Alexion Pharma (ALXN) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Pharma (ALXN) Gains Amid Conference Call
January 29, 2015 10:29 AM ESTAlexion Pharma (NASDAQ: ALXN) gained on statements made during its conference call.
It sees Q1 product revenue of $585-$590. 2015 tax rate is seen at 7%-9% vs 13%-15% prior. It expected US and EU decisions on Asfotase Alfa by mid-year, and Japan by the end of the year.
... MoreAlexion Pharma (ALXN) CEO Bell to Retire; Successor Named
January 29, 2015 6:31 AM ESTAlexion Pharma (NASDAQ: ALXN) announced that its Board of Directors has appointed David L. Hallal as the Companys Chief Executive Officer (CEO), effective April 1, 2015. Mr. Hallal currently serves as Alexions Chief Operating Officer (COO) and is a Director of the Board. He will succeed Leonard Bell, M.D., Chairman and CEO, who will retire as CEO and continue to serve as Chairman of the Board. Dr. Bell was the principal founder of Alexion in 1992 and has served as CEO for the past 23 years.
Mr. Hallal, 48, has more than 25 years of experience in the... More
